CL2019000624A1 - Formulaciones de buprenorfina de liberación sostenida. - Google Patents
Formulaciones de buprenorfina de liberación sostenida.Info
- Publication number
- CL2019000624A1 CL2019000624A1 CL2019000624A CL2019000624A CL2019000624A1 CL 2019000624 A1 CL2019000624 A1 CL 2019000624A1 CL 2019000624 A CL2019000624 A CL 2019000624A CL 2019000624 A CL2019000624 A CL 2019000624A CL 2019000624 A1 CL2019000624 A1 CL 2019000624A1
- Authority
- CL
- Chile
- Prior art keywords
- group
- undertaked
- alquilcarbonilo
- butanol
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UNA COMPOSICIÓN FARMACÉUTICAMENTE INYECTABLE QUE INCLUYE UNA SOLUCIÓN DE 3-ACILBUPRENORFINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA, EN UN SOLVENTE ORGÁNICO BIOCOMPATIBLE, EN DONDE LA COMPOSICIÓN FARMACÉUTICA INYECTABLE EXHIBE UN PERFIL DE LIBERACIÓN ESTABLE QUE SE MANTIENE DURANTE UNA SEMANA CUANDO SE INYECTA A UN PACIENTE. EL GRUPO ACILO ES UN GRUPO ALQUILCARBONILO, EN DONDE UNA PORCIÓN ALQUILO DEL GRUPO ALQUILCARBONILO ES UNA CADENA LINEAL O UNA CADENA RAMIFICADA, QUE TIENE 1-20 ÁTOMOS DE CARBONO. EL SOLVENTE ORGÁNICO BIOCOMPATIBLE ES N-METIL-2-PIRROLIDONA, ACETATO DE ETILO, ETANOL, BUTANOL, 2-BUTANOL, ISOBUTANOL, ISOPROPANOL, GLICERINA, BENZOATO DE BENCILO, DIMETILSULFÓXIDO, N,N-DIMETILACETAMIDA, PROPILENGLICOL, DIMETILGLICOL, ALCOHOL BENCÍLICO O UNA COMBINACIÓN DE DOS O MÁS DE LOS MISMOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394168P | 2016-09-13 | 2016-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000624A1 true CL2019000624A1 (es) | 2019-06-14 |
Family
ID=61619029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000624A CL2019000624A1 (es) | 2016-09-13 | 2019-03-12 | Formulaciones de buprenorfina de liberación sostenida. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10744132B2 (es) |
| EP (1) | EP3512518B1 (es) |
| JP (1) | JP6929367B2 (es) |
| KR (1) | KR102244500B1 (es) |
| CN (1) | CN109789137B (es) |
| AR (1) | AR110468A1 (es) |
| AU (1) | AU2017325910B2 (es) |
| BR (1) | BR112019004923A2 (es) |
| CA (1) | CA3033046C (es) |
| CL (1) | CL2019000624A1 (es) |
| CO (1) | CO2019003632A2 (es) |
| DK (1) | DK3512518T3 (es) |
| ES (1) | ES2934721T3 (es) |
| FI (1) | FI3512518T3 (es) |
| HR (1) | HRP20230062T8 (es) |
| HU (1) | HUE060906T2 (es) |
| LT (1) | LT3512518T (es) |
| MX (1) | MX2019002675A (es) |
| MY (1) | MY196269A (es) |
| PE (1) | PE20190707A1 (es) |
| PH (1) | PH12019500466A1 (es) |
| PL (1) | PL3512518T3 (es) |
| PT (1) | PT3512518T (es) |
| RS (1) | RS63894B1 (es) |
| RU (1) | RU2747306C2 (es) |
| SG (1) | SG11201901294QA (es) |
| SI (1) | SI3512518T1 (es) |
| TW (1) | TWI743193B (es) |
| WO (1) | WO2018050043A1 (es) |
| ZA (1) | ZA201900890B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057075C (zh) * | 1997-09-10 | 2000-10-04 | 中国石油化工总公司 | 低碳烯烃直接水合连续生产低碳醇的方法 |
| CN111954672B (zh) * | 2018-05-11 | 2023-09-01 | 昱展新药生技股份有限公司 | 丁丙诺啡衍生物的长效注射制剂及结晶形式 |
| AU2019416507A1 (en) * | 2018-12-27 | 2021-06-03 | Alar Pharmaceuticals Inc. | Naltrexone injectable sustained release formulation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001015699A1 (en) | 1999-08-27 | 2001-03-08 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
| ATE444296T1 (de) | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
| TWI226830B (en) * | 2002-11-12 | 2005-01-21 | Chi Mei Foundation Medical Ct | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions |
| CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物 |
| EP1422230B1 (en) * | 2002-11-25 | 2007-12-26 | Chi Mei Foundation Medical Center | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions |
| ES2309766T3 (es) | 2004-06-04 | 2008-12-16 | Camurus Ab | Formulaciones liquidas de liberacion lenta. |
| KR20080071185A (ko) * | 2005-11-21 | 2008-08-01 | 쉐링-프라우 리미티드 | 부프레노르핀을 포함하는 약제학적 조성물 |
| GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
| WO2008036980A1 (en) * | 2006-09-22 | 2008-03-27 | Alltranz Inc. | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
| US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
| GB2513060B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
| FR2975912B1 (fr) * | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | Composition a liberation controlee de buprenorphine |
| US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
-
2017
- 2017-09-12 SG SG11201901294QA patent/SG11201901294QA/en unknown
- 2017-09-12 HR HRP20230062TT patent/HRP20230062T8/hr unknown
- 2017-09-12 US US16/098,864 patent/US10744132B2/en active Active
- 2017-09-12 CN CN201780055635.3A patent/CN109789137B/zh active Active
- 2017-09-12 AU AU2017325910A patent/AU2017325910B2/en active Active
- 2017-09-12 PT PT178502456T patent/PT3512518T/pt unknown
- 2017-09-12 LT LTEPPCT/CN2017/101327T patent/LT3512518T/lt unknown
- 2017-09-12 RS RS20230034A patent/RS63894B1/sr unknown
- 2017-09-12 PE PE2019000487A patent/PE20190707A1/es unknown
- 2017-09-12 DK DK17850245.6T patent/DK3512518T3/da active
- 2017-09-12 PL PL17850245.6T patent/PL3512518T3/pl unknown
- 2017-09-12 TW TW106131215A patent/TWI743193B/zh active
- 2017-09-12 FI FIEP17850245.6T patent/FI3512518T3/fi active
- 2017-09-12 RU RU2019102895A patent/RU2747306C2/ru active
- 2017-09-12 BR BR112019004923A patent/BR112019004923A2/pt active Search and Examination
- 2017-09-12 ES ES17850245T patent/ES2934721T3/es active Active
- 2017-09-12 SI SI201731295T patent/SI3512518T1/sl unknown
- 2017-09-12 HU HUE17850245A patent/HUE060906T2/hu unknown
- 2017-09-12 MY MYPI2019000910A patent/MY196269A/en unknown
- 2017-09-12 CA CA3033046A patent/CA3033046C/en active Active
- 2017-09-12 EP EP17850245.6A patent/EP3512518B1/en active Active
- 2017-09-12 JP JP2019535434A patent/JP6929367B2/ja active Active
- 2017-09-12 KR KR1020197009185A patent/KR102244500B1/ko active IP Right Grant
- 2017-09-12 WO PCT/CN2017/101327 patent/WO2018050043A1/en unknown
- 2017-09-12 MX MX2019002675A patent/MX2019002675A/es active IP Right Grant
- 2017-09-13 AR ARP170102519A patent/AR110468A1/es unknown
-
2019
- 2019-02-12 ZA ZA2019/00890A patent/ZA201900890B/en unknown
- 2019-03-01 PH PH12019500466A patent/PH12019500466A1/en unknown
- 2019-03-12 CL CL2019000624A patent/CL2019000624A1/es unknown
- 2019-04-11 CO CONC2019/0003632A patent/CO2019003632A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002410A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| CL2020002748A1 (es) | Inhibidores de cinasa dependientes de ciclina | |
| CY1122730T1 (el) | 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων | |
| CL2019000624A1 (es) | Formulaciones de buprenorfina de liberación sostenida. | |
| CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
| CY1122838T1 (el) | Τοπικες συνθεσεις οι οποιες περιλαμβανουν φιπρονιλη και περμεθρινη και μεθοδοι χρησης | |
| CY1119453T1 (el) | Λυοφιλοποιημενη παρασκευη κυτταροτοξικων διπεπτιδιων | |
| CR20120418A (es) | Inhibidores de virus flaviviridae | |
| BR112017004448A2 (pt) | uso de agente de reforço de receptor gabaa na preparação de medicamento sedativo e anestésico | |
| CY1121554T1 (el) | Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
| DOP2019000184A (es) | Inhibidores selectivos de jak1 | |
| EA201990501A1 (ru) | Фармацевтическая композиция | |
| CL2021001395A1 (es) | Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades. | |
| DOP2019000204A (es) | Dendrímeros terapéuticos | |
| CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
| CL2017002334A1 (es) | Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| PE20190328A1 (es) | Compuestos de carfilzomib pegilados | |
| CY1124782T1 (el) | Φαρμακοτεχνικες μορφες μακρας δρασης | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| CL2017003091A1 (es) | Formulaciones tópicas para la entrega de compuestos inhibidores hedgehog y uso de los mismos | |
| CR20160527A (es) | Derivados de carboxamida | |
| AR088735A1 (es) | Compuestos de tienopirimidina que son inhibidores de canal de potasio |